Instem plc European Medicines Agency Research Grant
May 03 2022 - 2:02AM
RNS Non-Regulatory
TIDMINS
Instem plc
03 May 2022
Instem plc
("Instem", the "Group" or the "Company")
European Medicines Agency Research Grant
Instem plc (AIM: INS), a leading provider of IT solutions to the
global life sciences market, announces that it has secured funding
as part of a EUR2.5m European Medicines Agency ("EMA") grant - with
the Company receiving c.12.5% of funds invested by the EMA.
As part of an industry and academic consortium of nine
beneficiaries, funded by EMA and led by Fraunhofer Institute for
Toxicology and Experimental Medicine (ITEM), Instem is
collaborating on a two-year research project to further investigate
the mutagenicity of different classes of N-nitrosamines ("NAs").
Humans may be exposed to this class of organic chemical compounds
by consuming certain foods, or through tobacco use. Some active
pharmaceutical ingredients also carry NAs as impurities from
production and/or storage or may cause their formation in the
gastrointestinal tract. Consequently, NA related risk has become a
focus for pharmaceutical and other regulatory authorities around
the world. The project will aim to distinguish highly potent from
less potent carcinogens.
Experts from Instem's In Silico Solutions group will be
participating in the project, and its Leadscope Model Applier
computational toxicology software suite and toxicity and
carcinogenicity databases will be used to help the consortium
develop novel in silico test systems that will improve risk
assessment and derive reference doses such as acceptable intake
values.
Renowned for its advanced informatics and prediction technology,
together with comprehensive database solutions, Instem's in silico
solutions enable organizations around the world to effectively
unlock valuable knowledge contained in both public and proprietary
sources of research data. Its clients can access over 500,000
toxicology studies for more than 200,000 chemicals, enabling fast,
accurate, defendable and regulatory-accepted predictions.
Dr. Glenn Myatt, VP Informatics, Instem commented: " The
Leadscope Model Applier software solution includes a comprehensive
package of models to meet the growing market demand for in silico
solutions. The award of this grant highlights the strength of our
product suite, which supports the continued global demand for
reliable alternatives to traditional testing methods - with
industry and regulators alike increasingly recognizing the huge
benefits of computational toxicology approaches.
"We are delighted to have been invited to contribute to this
important research program and to have the opportunity to work with
leading researchers in developing new testing methodologies to help
reduce drug safety risks."
For further information, please contact:
Instem plc Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
Singer Capital Markets (Nominated
Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel
Alex Bond
Rachel Hayes
Stifel Nicolaus Europe Limited (Joint
Broker) +44 (0) 20 7710 7600
Ben Maddison
Alex Price
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
About Instem
Instem is a leading provider of IT solutions & services to
the life sciences market delivering compelling solutions for Study
Management, Regulatory Submissions, Clinical Trial Acceleration,
and Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide,
including all of the largest 25 pharmaceutical companies, enabling
clients to bring life enhancing products to market faster. Instem's
portfolio of software solutions increases client productivity by
automating study-related processes while offering the unique
ability to generate new knowledge through the extraction and
harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug
development value chain, from discovery through to market launch.
Management estimate that over 50% of all drugs on the market have
been through some part of Instem's platform during their
development.
To learn more about Instem solutions and its mission, please visit www.instem.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAILMJTMTJTBMT
(END) Dow Jones Newswires
May 03, 2022 02:02 ET (06:02 GMT)
Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Instem (LSE:INS)
Historical Stock Chart
From Jul 2023 to Jul 2024